Product
Adjuvant Atezolizumab-Bevacizumab Therapy
1 clinical trial
1 indication
Indication
Hepatocellular CarcinomaClinical trial
Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma (HCC)Status: Recruiting, Estimated PCD: 2027-03-01